These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17999563)

  • 1. Perspectives of I(f) inhibition by ivabradine in cardiology.
    Böhm M; Reil JC
    Drugs; 2007; 67 Suppl 2():43-9. PubMed ID: 17999563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical results of I(f) current inhibition by ivabradine.
    Tardif JC
    Drugs; 2007; 67 Suppl 2():35-41. PubMed ID: 17999562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel If current inhibitor ivabradine: safety considerations.
    Savelieva I; Camm AJ
    Adv Cardiol; 2006; 43():79-96. PubMed ID: 16936474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart rate lowering by inhibition of the pacemaker current: a new therapeutic perspective in cardiovascular disease.
    Dilaveris P; Giannopoulos G; Synetos A; Gatzoulis K; Stefanadis C
    Cardiovasc Hematol Agents Med Chem; 2006 Oct; 4(4):313-8. PubMed ID: 17073608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The funny current: cellular basis for the control of heart rate.
    DiFrancesco D; Borer JS
    Drugs; 2007; 67 Suppl 2():15-24. PubMed ID: 17999560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical perspectives of heart rate slowing for coronary event reduction and heart failure.
    Danchin N; Kadri Z
    Adv Cardiol; 2006; 43():45-53. PubMed ID: 16936471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
    Tardif JC
    Drugs Today (Barc); 2008 Mar; 44(3):171-81. PubMed ID: 18536779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-ischaemic effect of ivabradine.
    Ferrari R; Cargnoni A; Ceconi C
    Pharmacol Res; 2006 May; 53(5):435-9. PubMed ID: 16644235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate reduction by pharmacological If current inhibition.
    Cargnoni A; Ceconi C; Stavroula G; Ferrari R
    Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate reduction in heart failure: ivabradine or beta blockers?
    Guglin M
    Heart Fail Rev; 2013 Jul; 18(4):517-28. PubMed ID: 22972475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A; Tardif JC
    Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.